Working… Menu
Trial record 1 of 2364 for:    prostate cancer AND Urogenital Neoplasms | ( Map: United States )
Previous Study | Return to List | Next Study

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01540994
Recruitment Status : Unknown
Verified April 2017 by Geoffrey Weinstein, M.D., Sharp HealthCare.
Recruitment status was:  Recruiting
First Posted : February 29, 2012
Last Update Posted : May 1, 2017
Information provided by (Responsible Party):
Geoffrey Weinstein, M.D., Sharp HealthCare

Brief Summary:
The purpose of this study is to evaluate a short course (five radiation treatments) of very focused ("stereotactic") external beam radiation therapy for the treatment of early stage prostate cancer.

Condition or disease Intervention/treatment Phase
Prostatic Neoplasm Radiation: radiation therapy Phase 1 Phase 2

Detailed Description:
External beam radiation therapy for prostate cancer, while effective, takes up to 9 weeks to deliver on a Monday through Friday basis. Recent phase I/II studies from Seattle and Palo Alto using stereotactic guidance to deliver high doses of radiation to the prostate over a 1 to 2 week period of time suggest that outcomes may be equal or superior to standard approaches. These data, combined with markedly improved convenience for patients, make radiosurgery (SBRT) for early-stage prostate cancer an enticing option. The goal of this study is to offer a radiosurgical option to patients within the Sharp system under the umbrella of an IRB-approved study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Trial of Stereotactic Hypofractionated Radiotherapy of the Prostate
Study Start Date : January 2011
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: SBRT
Stereotactic Body Radiation Therapy
Radiation: radiation therapy
Stereotactic Body Radiation Therapy

Primary Outcome Measures :
  1. acute and late toxicity to the GU and GI systems [ Time Frame: 1 year follow-up ]
    acute and late toxicity to the GU and GI systems based on the RTOG definitions will be compared to those of standard radiation therapy.

Secondary Outcome Measures :
  1. Drop in the PSA (biochemical marker) [ Time Frame: 1 year follow-up ]
    One year biochemical control rate of >90%.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male with any age (typically 50 to 70 years old) with a low risk disease. This is defined as a Gleason's score of 6 or less, clinical stage of T2a or less, and a PSA of less than 15. We will also include patients with Gleason's score of 3+4=7 if there are fewer than 2 cores positive, with no more than 5mm of tumor in aggregate dimension.

Exclusion Criteria:

  • Prior surgery or radiotherapy for prostate cancer, PSA over 10, Gleason scores 7, 8, 9, or 10 (except Gleason 7 as noted, above), or clinical stage T2b, T2c, T3, or T4.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01540994

Layout table for location contacts
Contact: Geoffrey Weinstein, M.D. 858-939-5010

Layout table for location information
United States, California
Sharp Memorial Hospital Recruiting
San Diego, California, United States, 92123
Contact: Geoffrey Weinstein, M.D.    858-939-5010   
Principal Investigator: Geoffrey Weinstein, M.D.         
Sponsors and Collaborators
Sharp HealthCare
Layout table for investigator information
Principal Investigator: Geoffrey Weinstein, M.D. Sharp HealthCare

Layout table for additonal information
Responsible Party: Geoffrey Weinstein, M.D., Medical Director, Radiation Oncology, Sharp HealthCare Identifier: NCT01540994     History of Changes
Other Study ID Numbers: 101091
First Posted: February 29, 2012    Key Record Dates
Last Update Posted: May 1, 2017
Last Verified: April 2017
Keywords provided by Geoffrey Weinstein, M.D., Sharp HealthCare:
Urogenital neoplasm
Genital neoplasms, male
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases